948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): Results from a randomised, open-label, phase 3 trial
    Journal Article

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • A first-in-human study of cinrebafusp alfa, a HER2/4-1BB bispecific molecule, in patients with HER2-positive advanced solid malignancies
    Journal Article

    Piha-Paul, S.; Olwill, S. A.; Hamilton, E.; Tolcher, A.; Pohlmann, P.; Liu, S. V.; Wurzenberger, C.; Hasenkamp, L. C.; Hansbauer, E. M.; Shroff, R.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Phase II study of palbociclib in patients with tumors with CDK4 or CDK6 amplification: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1C
    Journal Article

    O’Hara, M. H.; Jegede, O.; Dickson, M. A.; DeMichele, A. M.; Piekarz, R.; Gray, R. J.; Wang, V.; McShane, L. M.; Rubinstein, L. V.; Patton, D. R.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Stereotactic body radiation therapy for primary renal cell carcinoma: A case-based radiosurgery society practice guide
    Journal Article

    Barbour, A. B.; Upadhyay, R.; Anderson, A. C.; Kutuk, T.; Kumar, R.; Wang, S. J.; Psutka, S. P.; Fekrmandi, F.; Skalina, K. A.; Bruynzeel, A. M. E.; more...
    Practical Radiation Oncology (2025)

    Fulltext@MSK | Save
  • A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
    Journal Article

    Hughes, B. G. M.; Guminski, A.; Bowyer, S.; Migden, M. R.; Schmults, C. D.; Khushalani, N. I.; Chang, A. L. S.; Grob, J. J.; Lewis, K. D.; Ansstas, G.; more...
    Journal of the American Academy of Dermatology (2025)

    Fulltext@MSK | Save
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study
    Journal Article

    Zinzani, P. L.; Izutsu, K.; Mehta-Shah, N.; Barta, S. K.; Ishitsuka, K.; Córdoba, R.; Kusumoto, S.; Bachy, E.; Cwynarski, K.; Gritti, G.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer
    Journal Article

    Yang, J. C. H.; Lee, D. H.; Lee, J. S.; Fan, Y.; de Marinis, F.; Iwama, E.; Inoue, T.; Rodríguez-Cid, J.; Zhang, L.; Yang, C. T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A qualitative study of attitudes and perceptions of smoking cessation medication among patients with cancer
    Journal Article

    Gittleman, J.; Cloutier, J. G.; Park, E. R.; Rasmussen, A.; Ponzani, C.; Weinberger, A. H.; Ostroff, J. S.; Perez, G.
    Supportive Care in Cancer (2024)

    Fulltext@MSK | Save
  • Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: Results from the open-label, randomised, phase II FRACTION-RCC trial
    Journal Article

    Choueiri, T. K.; Kuzel, T. M.; Tykodi, S. S.; Verzoni, E.; Kluger, H.; Nair, S.; Perets, R.; George, S.; Gurney, H.; Pachynski, R. K.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors
    Journal Article

    Lenz, H. J.; Argilés, G.; de Jonge, M. J. A.; Yaeger, R.; Doi, T.; El-Khoueiry, A.; Eskens, F.; Kuboki, Y.; Bertulis, J.; Nazabadioko, S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save